210 related articles for article (PubMed ID: 26632889)
1. Relation Between F-18 FDG Uptake of PET/CT and BRAFV600E Mutation in Papillary Thyroid Cancer.
Yoon S; An YS; Lee SJ; So EY; Kim JH; Chung YS; Yoon JK
Medicine (Baltimore); 2015 Dec; 94(48):e2063. PubMed ID: 26632889
[TBL] [Abstract][Full Text] [Related]
2. Relationship Between
Chang JW; Park KW; Heo JH; Jung SN; Liu L; Kim SM; Kwon IS; Koo BS
World J Surg; 2018 Jan; 42(1):114-122. PubMed ID: 28808756
[TBL] [Abstract][Full Text] [Related]
3. Relationships between transporter expression and the status of BRAF V600E mutation and F-18 FDG uptake in papillary thyroid carcinomas.
Yoon M; Jung SJ; Kim TH; Ha TK; Urm SH; Park JS; Lee SM; Bae SK
Endocr Res; 2016; 41(1):64-9. PubMed ID: 26513490
[TBL] [Abstract][Full Text] [Related]
4. Clinicopathological characteristics including BRAF V600E mutation status and PET/CT findings in papillary thyroid carcinoma.
Choi EK; Chong A; Ha JM; Jung CK; O JH; Kim SH
Clin Endocrinol (Oxf); 2017 Jul; 87(1):73-79. PubMed ID: 28329426
[TBL] [Abstract][Full Text] [Related]
5. Prognostic implication of fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography in patients with recurrent papillary thyroid cancer.
Kang JH; Jung DW; Pak KJ; Kim IJ; Kim HJ; Cho JK; Shin SC; Wang SG; Lee BJ
Head Neck; 2018 Jan; 40(1):94-102. PubMed ID: 29130586
[TBL] [Abstract][Full Text] [Related]
6. Correlation of BRAF mutation and SUV
Ozderya A; Temizkan S; Gul AE; Ozugur S; Sargin M; Aydin K
Endocrine; 2017 Jan; 55(1):215-222. PubMed ID: 27696232
[TBL] [Abstract][Full Text] [Related]
7. Correlation of BRAFV600E Mutation and Glucose Metabolism in Thyroid Cancer Patients: An ¹⁸F-FDG PET Study.
Nagarajah J; Ho AL; Tuttle RM; Weber WA; Grewal RK
J Nucl Med; 2015 May; 56(5):662-7. PubMed ID: 25814520
[TBL] [Abstract][Full Text] [Related]
8. Clinical value of visually identifiable 18F-fluorodeoxyglucose uptake in primary papillary thyroid microcarcinoma.
Hwang SO; Lee SW; Kang JK; Choi HH; Kim WW; Park HY; Jung JH
Otolaryngol Head Neck Surg; 2014 Sep; 151(3):415-20. PubMed ID: 24903453
[TBL] [Abstract][Full Text] [Related]
9. Non-FDG-avid primary papillary thyroid carcinoma may not differ from FDG-avid papillary thyroid carcinoma.
Kim MH; Ko SH; Bae JS; Lee SH; Jung CK; Lim DJ; Baek KH; Kim SH; Lee JM; Kang MI; Cha BY
Thyroid; 2013 Nov; 23(11):1452-60. PubMed ID: 23688271
[TBL] [Abstract][Full Text] [Related]
10. Analysis of predictability of F-18 fluorodeoxyglucose-PET/CT in the recurrence of papillary thyroid carcinoma.
Kim SK; So Y; Chung HW; Yoo YB; Park KS; Hwang TS; Kim B; Lee WW
Cancer Med; 2016 Oct; 5(10):2756-2762. PubMed ID: 27539659
[TBL] [Abstract][Full Text] [Related]
11. PROGNOSTIC VALUE OF LYMPH NODE UPTAKE ON PRETREATMENT F-18 FDG PET/CT IN PATIENTS WITH N1B PAPILLARY THYROID CARCINOMA.
Lee CH; Lee SW; Son SH; Hong CM; Jeong JH; Jeong SY; Ahn BC; Lee J
Endocr Pract; 2019 Aug; 25(8):787-793. PubMed ID: 31013158
[No Abstract] [Full Text] [Related]
12. THE RELATIONSHIP OF BRAF
Santhanam P; Khthir R; Solnes LB; Ladenson PW
Endocr Pract; 2018 Jan; 24(1):21-26. PubMed ID: 29144823
[TBL] [Abstract][Full Text] [Related]
13. Feasibility of FDG-PET/CT for the initial diagnosis of papillary thyroid cancer.
Kim H; Na KJ; Choi JH; Ahn BC; Ahn D; Sohn JH
Eur Arch Otorhinolaryngol; 2016 Jun; 273(6):1569-76. PubMed ID: 25971994
[TBL] [Abstract][Full Text] [Related]
14. Factors associated with positive F-18 flurodeoxyglucose positron emission tomography before thyroidectomy in patients with papillary thyroid carcinoma.
Kim BS; Kim SJ; Kim IJ; Pak K; Kim K
Thyroid; 2012 Jul; 22(7):725-9. PubMed ID: 22524470
[TBL] [Abstract][Full Text] [Related]
15. mRNA Expression of SLC5A5 and SLC2A Family Genes in Papillary Thyroid Cancer: An Analysis of The Cancer Genome Atlas.
Suh S; Kim YH; Goh TS; Jeong DC; Lee CS; Jang JY; Cha W; Han ME; Kim SJ; Kim IJ; Pak K
Yonsei Med J; 2018 Aug; 59(6):746-753. PubMed ID: 29978611
[TBL] [Abstract][Full Text] [Related]
16. Prevalence and significance of thyroid uptake detected by ¹⁸F-FDG PET.
Ho TY; Liou MJ; Lin KJ; Yen TC
Endocrine; 2011 Oct; 40(2):297-302. PubMed ID: 21505891
[TBL] [Abstract][Full Text] [Related]
17. Clinical implications of the BRAF mutation in papillary thyroid carcinoma and chronic lymphocytic thyroiditis.
Kim WW; Ha TK; Bae SK
J Otolaryngol Head Neck Surg; 2018 Jan; 47(1):4. PubMed ID: 29316976
[TBL] [Abstract][Full Text] [Related]
18. [Clinical pathological characteristics of resectable papillary thyroid microcarcinoma].
Shi CL; Guo Y; Lyu YC; Nanding ZABYS; Gao WC; Shi TF; Qin HD; Liu SY
Zhonghua Zhong Liu Za Zhi; 2017 May; 39(5):361-366. PubMed ID: 28535653
[No Abstract] [Full Text] [Related]
19. BRAF in primary and recurrent papillary thyroid cancers: the relationship with (131)I and 2-[(18)F]fluoro-2-deoxy-D-glucose uptake ability.
Barollo S; Pennelli G; Vianello F; Watutantrige Fernando S; Negro I; Merante Boschin I; Pelizzo MR; Rugge M; Mantero F; Nacamulli D; Girelli ME; Busnardo B; Mian C
Eur J Endocrinol; 2010 Oct; 163(4):659-63. PubMed ID: 20647301
[TBL] [Abstract][Full Text] [Related]
20. Real-Time PCR Cycle Threshold Values for the BRAFV600E Mutation in Papillary Thyroid Microcarcinoma May Be Associated With Central Lymph Node Metastasis: A Retrospective Study.
Park VY; Kim EK; Lee HS; Moon HJ; Yoon JH; Kwak JY
Medicine (Baltimore); 2015 Jul; 94(28):e1149. PubMed ID: 26181555
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
